Lornoxicam

Lornoxicam (Chlortenoxicam) is an orally active oxycontin nonsteroidal anti-inflammatory drug (NSAID) with analgesic, anti-inflammatory, antipyretic and anticancer activities. Lornoxicam exhibits good inhibitory effects on both COX-1 and COX-2 (COX-1: IC50=0.005 μM; COX-2:IC50=0.008 μM) and inhibits the production of NO by iNOS (IC50=65 μM) and the proinflammatory cytokine IL-6 (IC50=54 μM) . Lornoxicam also inhibits tumor cell proliferation and migration and induces tumor cell apoptosis. Lornoxicam can be used in the study of inflammatory pain, colorectal cancer and breast cancer[1][2][3][4][5][6][7].

Product Specifications

CAS Number

[70374-39-9]

Product Name Alternative

Chlortenoxicam; Ro 13-9297

UNSPSC

12352005

Hazard Statement

H300

Target

Apoptosis; COX; Interleukin Related; NO Synthase; Prostaglandin Receptor; TNF Receptor

Type

Natural Products

Related Pathways

Apoptosis; GPCR/G Protein; Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/Lornoxicam.html

Purity

99.36

Solubility

DMSO : 3.8 mg/mL (ultrasonic; warming)

Smiles

O=C(C1=C(O)C2=C(C=C(Cl)S2)S(N1C)(=O)=O)NC3=NC=CC=C3

Molecular Formula

C13H10ClN3O4S2

Molecular Weight

371.82

Precautions

H300

References & Citations

[1]Spyra S, et al. COX-2-selective inhibitors celecoxib and deracoxib modulate transient receptor potential vanilloid 3 channels. Br J Pharmacol. 2017 Aug;174 (16) :2696-2705.|[2]Rose, P. and C. Steinhauser, Comparison of Lornoxicam and Rofecoxib in Patients with Activated Osteoarthritis (COLOR Study) . Clin Drug Investig, 2004. 24 (4) : p. 227-36.|[3]Bianchi, M. and A.E. Panerai, Effects of lornoxicam, piroxicam, and meloxicam in a model of thermal hindpaw hyperalgesia induced by formalin injection in rat tail. Pharmacol Res, 2002. 45 (2) : p. 101-5.|[4]Balfour J A, et al. Lornoxicam: a review of its pharmacology and therapeutic potential in the management of painful and inflammatory conditions[J]. Drugs, 1996, 51: 639-657.|[5]Pohlmeyer-Esch G, et al. Evaluation of chronic oral toxicity and carcinogenic potential of lornoxicam in rats[J]. Food and chemical toxicology, 1997, 35 (9) : 909-922.|[6]Berg J, et al. The analgesic NSAID lornoxicam inhibits cyclooxygenase (COX) -1/-2, inducible nitric oxide synthase (iNOS), and the formation of interleukin (IL) -6 in vitro[J]. Inflammation Research, 1999, 48: 369-379.|[7]Marinov L, et al. The effects of meloxicam, lornoxicam, ketoprofen, and dexketoprofen on human cervical, colorectal, and mammary carcinoma cell lines[J]. Pharmacia, 2024, 71: 1-12.